Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 17/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PER2 | O15055 | 1/20 | 0.49 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.49 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28701935 | 1.00 | DNM1 (0.52) | DNM1MITFALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL29558821 | 1.00 | DNM1 (0.52) | DNM1MITFALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL30145482 | 1.00 | DNM1 (0.52) | DNM1MITFALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL29558281 | 1.00 | DNM1 (0.52) | DNM1MITFALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL17147695 | 1.00 | DNM1 (0.52) | DNM1MITFALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL17147693 | 1.00 | DNM1 (0.52) | DNM1MITFALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL17147690 | 0.85 | PER2 (0.53) | PER2CRY1CRY2 | |
| SCHEMBL17147692 | 0.85 | PER2 (0.53) | PER2CRY1CRY2 | |
| SCHEMBL17147694 | 0.85 | PER2 (0.53) | PER2CRY1CRY2 | |
| SCHEMBL29558339 | 0.85 | PER2 (0.53) | PER2CRY1CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | DNM1 2945/4885MITF 1789/4885ALDH1A1 2882/4885 |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | DNM1 2945/4885MITF 1789/4885ALDH1A1 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.